• Home
  • Store
    • Total Access Subscriptions
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • Toolkit
  • FAQs
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Access Purchased Content
Home » Authors » Daniel Carlat, MD

Daniel Carlat, MD

Dr. Carlat has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Articles
Products

ARTICLES

Fact Sheet

Olanzapine (Lybalvi, Symbyax, Zyprexa) Fact Sheet [G] for General Psychiatry

January 1, 2026
Talia Puzantian, PharmD, BCPP and Daniel Carlat, MD

Dr. Carlat and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Many consider olanzapine to be more effective than other antipsychotics and just below clozapine in overall efficacy. Its strong effectiveness, once-daily dosing, and low QT-prolongation risk are appealing.



Read More
Fact Sheet

Major Neurocognitive Disorder: Medication Treatment

January 1, 2026
Victoria Hendrick, MD and Daniel Carlat, MD

Dr. Carlat and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

There is no cure for major neurocognitive disorder (MND), but several medications mitigate the progression of cognitive and functional decline.


Read More
Fact Sheet

Methadone (Methadose) Fact Sheet [G]

January 1, 2026
Talia Puzantian, PharmD, BCPP and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Methadone is a long-acting opioid and a mainstay of opioid use disorder (OUD) treatment.


Read More
Fact Sheet

Buprenorphine (Brixadi, Sublocade) Fact Sheet [G]

January 1, 2026
Talia Puzantian, PharmD, BCPP and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Buprenorphine (Subutex, available now only as generic) is the active ingredient in Suboxone (buprenorphine/naloxone) and is responsible for the effectiveness of the combination medication in opioid use disorder. 


Read More
Fact Sheet

Bright Light Therapy Fact Sheet

January 1, 2026
Talia Puzantian, PharmD, BCPP and Daniel Carlat, MD

Dr. Puzantian and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Light therapy is an effective treatment for seasonal affective disorder and possibly for nonseasonal depression as well. 


Read More
Fact Sheet

Tasimelteon (Hetlioz) Fact Sheet [G]

January 1, 2026
Talia Puzantian, PharmD, BCPP and Daniel Carlat, MD

Dr. Puzantian and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Tasimelteon is a melatonin receptor agonist approved for non-24-hour sleep-wake disorder (N24SWD), which occurs primarily in blind people.


Read More
Fact Sheet

Pitolisant (Wakix) Fact Sheet

January 1, 2026
Talia Puzantian, PharmD, BCPP and Daniel Carlat, MD

Dr. Puzantian and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Pitolisant is the only noncontrolled substance approved for narcolepsy, but limited experience and higher cost make it a second-line option after modafinil and armodafinil.


Read More
Fact Sheet

Solriamfetol (Sunosi) Fact Sheet

January 1, 2026
Talia Puzantian, PharmD, BCPP and Daniel Carlat, MD

Dr. Puzantian and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Solriamfetol is a wakefulness promoter with a different mechanism of action (dopamine and norepinephrine reuptake inhibition) from modafinil and armodafinil.


Read More
Fact Sheet

Oxybates (Lumryz, Xyrem, Xywav) Fact Sheet [G]

.
January 1, 2026
Talia Puzantian, PharmD, BCPP and Daniel Carlat, MD

Dr. Puzantian and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Melatonin is a hormone secreted by the pineal gland that helps regulate the sleep-wake cycle.



Read More
Fact Sheet

Modafinil (Provigil) Fact Sheet [G] for General Psychiatry

January 1, 2026
Talia Puzantian, PharmD, BCPP and Daniel Carlat, MD

Dr. Puzantian and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

While modafinil can be helpful for many causes of excessive sleepiness, realize that many people end up using it off-label for lifestyle enhancement, such as working, studying, and partying.


Read More
View All Articles by Daniel Carlat, MD
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • MFB8e_SpiralCover.png

    Medication Fact Book for Psychiatric Practice, Eighth Edition (2026)

    Updated 2026 prescriber's guide.
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • supportive psychotherapy Dalle 11082023.jpg
    Psychology and Social Work

    Treating BPD Series, Episode 2: Transference-Focused Psychotherapy—From Splitting to Coherence with Frank Yeomans, MD, PhD

    In this episode, Dr. Frank Yeomans offers a deep dive into the theory and clinical practice of TFP as a treatment for Borderline Personality Disorder.

    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2026 Carlat Publishing, LLC and Affiliates, All Rights Reserved.